OBR Daily Commentary

forumImage

OncoCyte Says Study Confirms Accuracy Of Lung Cancer Blood Test

(Reuters) Mar 6, 2017 - OncoCyte Corp, which is developing diagnostics in the fledgling field of liquid biopsies, said on Monday a 300-patient validation study of its blood test for early detection of lung cancer has confirmed the accuracy reported from a prior trial.

H. Jack West, MD (Posted: March 06, 2017)

quotesI'm dubious about a 62% specificity. The test doesn't conclusively rule out cancer, nor does it establish what we would consider to be a conclusive diagnosis. being priced aggressively, at 75-80% the cost of a biopsy estimated to cost $15K, I don't think this test will give 75-80% of the value of a biopsy. I am dubious it will emerge as a widely adopted test, at least at the aggressive price point at which it is being offered.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

In-House Specialty Pharmacy at Cancer Center Improves Quality of Care, Reduces Medical Errors

(2017 Quality Care Symposium) Feb 27, 2017 - An influx of new oral cancer drugs provides patients with a more convenient and less invasive way to take medication, but such treatments are often associated with adherence challenges and medical errors.

Winston Wong, PharmD (Posted: March 04, 2017)

quotesMost health plans require oral oncology agent to be dispensed through their specialty pharmacy program, with the promise by the specialty pharmacy for close monitoring for adverse effects and adherence. The problem, however, is that the oncologists are not kept informed of the patient issues, nor are they informed of a break in therapy. When the oral med is filled by the SP, a major disconnect usually happens. Maybe more effects is needed to provide integrated comprehensive care, as opposed to putting up barriers to oncology practices to stop them from coordinating the care of their patients.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

No Details Yet, But Genentech Drug Combo Wins in Big Breast Cancer Study

(Xconomy San Francisco) Mar 2, 2017 - There may be a new standard of care coming for a large portion of women with breast cancer who have had surgery to remove their tumors.

Dean Gesme, MD (Posted: March 02, 2017)

quotesAphinity is expected to be practice changing for Her2 positive early breast cancer patients not already treated with these agents in the neoadjuvant setting. I anticipate this to be a Plenary presentation at ASCO 2017.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Professor and Chair, Department of Radiation Oncology...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Health Policy
member photo
Joseph Bailes, MD

National Health Policy Expert...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Professor and Physician-in-Chief of the Ohios State Uni...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...